AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: Pharmacokinetics, glucodynamics, safety, and tolerability

Diabetes Care

Volumn 30, Issue 7, 2007, Pages 1777-1782

  Rave, Klaus ^a,e   De La Peña, Amparo ^b   Tibaldi, Fabián S ^c   Zhang, Liping ^b   Silverman, Bernard ^d   Hausmann, Michaela ^a   Heinemann, Lutz ^a   Muchmore, Douglas B ^b  

^a Profil Institute for Metabolic Research   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c Eli Lilly Benelux   (Belgium)

^d ALKERMES INC   (United States)

^e Profil Institut fur Stoffwechselforschung GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN LISPRO;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG EMPHYSEMA; LUNG FUNCTION; MALAISE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SPIROMETRY;

ADMINISTRATION, INHALATION; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 34447120052     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2284     Document Type: Article

References (24)

1. Elliott RB, Edgar BW, Pilcher CC, Quested C, McMaster J: Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J 23:293-297, 1987
2. Laube BL, Georgopoulos A, Adams GK III: Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 269:2106-2109, 1993 [erratum in JAMA 270:324, 1993]
3. Jendle JH, Karlberg BE: Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 56:555-561, 1996
4. Jendle JH, Karlberg BE: Intrapulmonary administration of insulin to healthy volunteers. J Intern Med 240:93-98, 1996
5. Heinemann L, Traut T, Heise T: Time-action profile of inhaled insulin. Diabet Med 14:63-72, 1997
6. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA: Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 27:1318-1323, 2004
7. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R: Large porous particles for pulmonary drug delivery. Science 276:1868-1871, 1997
8. Dunbar C, Scheuch G, Sommerer K, De-Long M, Verma A, Batycky R: In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int J Pharm 245:179-189, 2002
9. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, GOLD Scientific Committee: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46:798-825, 2001
10. American Thoracic Society: Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 152:1107-1136, 1995
11. Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS II, Heinemann L, Batycky RP, Muchmore DB: Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 28:2400-2405, 2005
12. Cleveland WS, Devlin SJ, Grosse E: Regression by local fitting: methods, properties, and computational algorithms. J Econometrics 37:87-114, 1988
13. MacNee W: Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:258 -266, 2005
14. Patton JS, Fishburn CS, Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 1:338 -344, 2004
15. Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peña A, Muchmore DB: Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 49:891-899, 2006
16. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614-1620, 2004
17. Heinemann L, Anderson JH Jr.: Measurement of insulin absorption and insulin action. Diabetes Technol Ther 6:698-718, 2004
18. Himmelmann A, Jendle J, Mellén A, Petersen AH, Dahl UL, Wollmer P: The impact of smoking on inhaled insulin. Diabetes Care 26:677-682, 2003
19. Pan A, Chan C, Loh MT, Yeo KP, Muchmore DB, Silverman B, de la Peña A, Wise SD: Effects of smoking (immediate and delayed), abstinence, nicotine replacement therapy, and smoking resumption on pulmonary insulin pharmacokinetics and glucodynamics (Abstract). Diabetes 53 (Suppl. 2):A112, 2004
20. Becker RHA, Sha S, Frick AD, Fountaine RJ: The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 29:277-282, 2006
21. Wise S, Chien J, Yeo K, Richardson C: Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. Diabet Med 23:510-515, 2006
22. Barnett AH: Exubera inhaled insulin: a review. Int J Clin Pract 58:394-401, 2004
23. Brain JD: Unlocking the opportunity of tight glycaemic control. Diabetes Obes Metab 7 (Suppl. 1):S14-S18, 2005
24. Muchmore DB, Gates JR: Inhaled insulin delivery: where are we now? Diabetes Obes Metab 8:634-642, 2006